Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience (ANRO) announced that management will participate in two upcoming healthcare investor conferences through fireside chats and one-on-one meetings.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/03/2026 - 08:03 AM EST

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:

Stifel 2026 Healthcare Conference, November 10-12, 2026
- Format: Fireside chat and one-on-one meetings
- Presentation Date & Time: Wednesday, November 11 at 8:00 AM ET
- Location: New York, New York
Jefferies London Healthcare Conference, November 16-19, 2026
- Format: Fireside chat and one-on-one investor meetings
- Presentation Date & Time: Thursday, November 19 at 9:30 AM GMT
- Location: London, UK

The presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.

About Alto Neuroscience

Alto Neuroscience (NYSE: ANRO) is a clinical-stage biopharmaceutical company on a mission to transform the treatment of mental health conditions through a deeper understanding of the brain. Leveraging its proprietary Precision Psychiatry Platform™, Alto is advancing a broad pipeline of novel medicines for depression, schizophrenia, and other neuropsychiatric disorders. The Company’s lead program, ALTO-207, is in late-stage clinical development for treatment-resistant depression. For more information, visit www.altoneuroscience.com or follow Alto on X.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.